이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

건강한 지원자를 대상으로 한 BCD101의 안전성 및 약동학 연구

2026년 9월 28일 업데이트: Bichedam Co., Ltd.

건강한 성인 자원자를 대상으로 BCD101의 안전성, 내약성 및 약동학적 특성을 평가하기 위한 무작위, 이중맹검, 단일/다중 투여, 용량 증량, 1상 임상시험

A randomized, double-blinded, single/multiple dosing, dose escalation Phase 1 clinical trial to evaluate the safety, tolerability, and pharmacokinetic characteristics of BCD101 in healthy adult volunteers.

The primary objectives of this study are to determine:

  1. The safety and tolerability of BCD101 in healthy adult volunteers.
  2. The pharmacokinetic profile of BCD101 following single and multiple dosing.

A control group is included, and dose cohorts will be compared to assess dose-dependent differences in safety, tolerability, and pharmacokinetics.

Key study activities include:

  1. Administration of single and multiple escalating doses of BCD101 and placebo under controlled conditions.
  2. Safety and tolerability assessments, including monitoring for adverse events (AEs), serious adverse events (SAEs), adverse drug reactions (ADRs), and serious adverse drug reactions (SADRs).
  3. Pharmacokinetic (PK) analysis to evaluate the pharmacokinetic characteristics of the investigational product.

연구 개요

연구 유형

중재적

등록 (실제)

57

단계

  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • North Chungcheong
      • Cheongju-si, North Chungcheong, 대한민국, 28644
        • Chungbuk National University Hospital

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

19년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

예

연구 대상 성별

모두

설명

  1. Inclusion Criteria

    • Healthy adult volunteers aged 19 years or older at screening.

    • Body weight ≥ 50.0 kg and body mass index (BMI) between 18.0 kg/m² and 30.0 kg/m² at screening.

      * BMI (kg/m²) = weight (kg) / {height (m)}²

    • No congenital or chronic medical conditions requiring treatment, and no pathological signs or findings upon medical examination.

    • Clinical laboratory tests, vital signs, physical examination, and 12-lead electrocardiogram (ECG) results at screening indicate suitability for participation based on the characteristics of the investigational medicinal product.

    • Fully understood the detailed explanation of this clinical trial, voluntarily agreed to participate, and provided written informed consent agreeing to comply with study requirements during the trial period.

  2. Exclusion Criteria

    • History or current clinically significant liver, kidney, neurological, psychiatric, respiratory, endocrine, hematological, neoplastic, genitourinary, cardiovascular, gastrointestinal, or musculoskeletal disorders.

    • Female subjects who are pregnant (urine hCG positive) or breastfeeding.

    • History of hypersensitivity (e.g., anaphylaxis, angioedema) or clinically significant allergic reactions to the active ingredient, excipients of the investigational product, or other medications (e.g., aspirin, penicillin antibiotics, macrolide antibiotics).

    • History of gastrointestinal diseases or surgeries that could affect absorption of the investigational drug (e.g., Crohn's disease, ulcers, acute or chronic pancreatitis), except simple appendectomy or hernia surgery.

    • Clinically significant abnormalities on 12-lead ECG at screening, including:

      • QTc interval > 450 ms (males) or > 470 ms (females)
      • PR interval > 200 ms
      • QRS duration > 120 ms
    • Clinically significant laboratory abnormalities at screening, including:

      • Liver function tests (AST, ALT, ALP, γ-GT, total bilirubin) exceeding twice the upper limit of normal.
      • Serum creatinine outside the reference range or estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73m² as calculated by the CKD-EPI formula.
    • History of substance abuse or positive urine drug screening for abuse substances.

Vital signs at screening after at least 3 minutes of rest in a seated position meet any of the following:

  • Systolic blood pressure ≤ 90 mmHg or ≥ 150 mmHg

  • Diastolic blood pressure ≤ 60 mmHg or ≥ 100 mmHg

  • Pulse rate ≤ 40 bpm or ≥ 100 bpm

    • Evidence of orthostatic hypotension at screening.
    • Use of enzyme-inducing or inhibiting drugs such as barbiturates within 1 month prior to first dosing.
    • Abnormal diet or consumption of foods that could affect drug absorption, distribution, metabolism, or excretion.
    • Use of prescription or herbal medications that may affect the investigational product's characteristics within 2 weeks prior to first dosing, or over-the-counter drugs or dietary supplements within 10 days prior to first dosing (except when judged by the investigator not to affect the pharmacokinetics of the investigational product).
    • Participation in another clinical trial with investigational drug administration within 6 months prior to first dosing (the end date of participation is calculated as the day after the last dose of the previous trial).
    • Whole blood donation within 2 months prior to first dosing, platelet donation within 1 month prior to first dosing, blood transfusion within 1 month prior to first dosing, or inability to abstain from blood donation from informed consent to PSV.
    • Excessive alcohol consumption (more than 21 units per week; 1 unit = 10 g = 12.5 mL pure alcohol) within 6 months prior to first dosing or inability to abstain from alcohol from informed consent to PSV.
    • Smoking more than 10 cigarettes per day within 3 months prior to first dosing or inability to abstain from smoking from 24 hours prior to first dosing until last blood sampling.
    • Consumption of grapefruit-containing foods within 72 hours prior to first dosing or inability to abstain until PSV.
    • Consumption of caffeine-containing foods or beverages (e.g., coffee, green tea, black tea, carbonated drinks, coffee milk, energy drinks) from 24 hours prior to first dosing until last blood sampling or inability to abstain.
    • Engaging in strenuous exercise exceeding daily activity levels from 48 hours prior to first dosing until PSV or inability to refrain from such exercise.
    • Planning to become pregnant or not using reliable contraception methods (e.g., hormonal contraceptives, intrauterine device, sterilization procedures, barrier methods) for self or partner from informed consent until 90 days after last dose of investigational product.
    • Any other reasons deemed by the investigator to make the subject unsuitable for participation.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 기초 과학
  • 할당: 무작위
  • 중재 모델: 순차적 할당
  • 마스킹: 네 배로

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: SAD-1(Treatment group)

6 Participants in the SAD-1(Treatment group) arm received a single oral dose of BCD101-1(2 sachets).

BCD101-1 is a low-dose liquid formulation containing 2 g of the active ingredient per 10 g sachet.

This study was conducted as a randomized, double-blinded, placebo-controlled, oral, single-dose, dose-escalation trial.

[SAD] A liquid formulation of BCD101-1 containing 2 g of the active ingredient per 10 g sachet, administered orally. Used for single dosing at low concentration.

[MAD] A liquid formulation of BCD101-1 containing 2 g of the active ingredient per 10 g sachet, administered orally. Used for multiple dosing at low concentration.

실험적: SAD-2(Treatment group)

6 Participants in the SAD-2(Treatment group) arm received a single oral dose of BCD101-2(2 sachets).

BCD101-2 is a high-dose liquid formulation containing 4 g of the active ingredient per 10 g sachet.

This study was conducted as a randomized, double-blinded, placebo-controlled, oral, single-dose, dose-escalation trial.

[SAD] A liquid formulation of BCD101-2 containing 4 g of the active ingredient per 10 g sachet, administered orally. Used for single dosing at high concentration.

[MAD] A liquid formulation of BCD101-2 containing 4 g of the active ingredient per 10 g sachet, administered orally. Used for multiple dosing at high concentration.

실험적: SAD-3(Treatment group)

6 Participants in the SAD-3(Treatment group) arm received a single oral dose of BCD101-2(3 sachets).

BCD101-2 is a high-dose liquid formulation containing 4 g of the active ingredient per 10 g sachet.

This study was conducted as a randomized, double-blinded, placebo-controlled, oral, single-dose, dose-escalation trial.

[SAD] A liquid formulation of BCD101-2 containing 4 g of the active ingredient per 10 g sachet, administered orally. Used for single dosing at high concentration.

[MAD] A liquid formulation of BCD101-2 containing 4 g of the active ingredient per 10 g sachet, administered orally. Used for multiple dosing at high concentration.

실험적: SAD-4(Treatment group)

6 Participants in the SAD-4(Treatment group) arm received a single oral dose of BCD101-2(4 sachets).

BCD101-2 is a high-dose liquid formulation containing 4 g of the active ingredient per 10 g sachet.

This study was conducted as a randomized, double-blinded, placebo-controlled, oral, single-dose, dose-escalation trial.

[SAD] A liquid formulation of BCD101-2 containing 4 g of the active ingredient per 10 g sachet, administered orally. Used for single dosing at high concentration.

[MAD] A liquid formulation of BCD101-2 containing 4 g of the active ingredient per 10 g sachet, administered orally. Used for multiple dosing at high concentration.

실험적: MAD-1(Treatment group)

6 Participants in the MAD-1(Treatment group) arm received BCD101-1(1 sachet), administered orally twice daily for 7 consecutive days.

BCD101-1 is a low-dose liquid formulation containing 2 g of the active ingredient per 10 g sachet.

This study was conducted as a randomized, double-blinded, placebo-controlled, multiple-dose, dose-escalation trial.

[SAD] A liquid formulation of BCD101-1 containing 2 g of the active ingredient per 10 g sachet, administered orally. Used for single dosing at low concentration.

[MAD] A liquid formulation of BCD101-1 containing 2 g of the active ingredient per 10 g sachet, administered orally. Used for multiple dosing at low concentration.

실험적: MAD-2(Treatment group)

6 Participants in the MAD-2(Treatment group) arm received BCD101-2(1 sachet), administered orally twice daily for 7 consecutive days.

BCD101-2 is a high-dose liquid formulation containing 4 g of the active ingredient per 10 g sachet.

This study was conducted as a randomized, double-blinded, placebo-controlled, multiple-dose, dose-escalation trial.

[SAD] A liquid formulation of BCD101-2 containing 4 g of the active ingredient per 10 g sachet, administered orally. Used for single dosing at high concentration.

[MAD] A liquid formulation of BCD101-2 containing 4 g of the active ingredient per 10 g sachet, administered orally. Used for multiple dosing at high concentration.

실험적: MAD-3(Treatment group)

6 Participants in the MAD-3(Treatment group) arm received a combination of BCD101-1(1 sachet) and BCD101-2(1 sachet), administered orally twice daily for 7 consecutive days.

BCD101-1 is a low-dose liquid formulation containing 2 g of the active ingredient per 10 g sachet, while BCD101-2 is a high-dose liquid formulation containing 4 g of the active ingredient per 10 g sachet.

This study was conducted as a randomized, double-blinded, placebo-controlled, multiple-dose, dose-escalation trial.

[MAD] A combination of BCD101-1(2 g) and BCD101-2(4 g) liquid formulations, administered orally as separate sachets simultaneously. Used for multiple dosing.

실험적: SAD-1(Placebo group)

2 Participants in the SAD-1(Placebo group) arm received a single oral dose of BCD101-P(2 sachets).

BCD101-P is a placebo liquid formulation identical in appearance and volume to BCD101-1, containing no active ingredient.

This study was conducted as a randomized, double-blinded, placebo-controlled, oral, single-dose, dose-escalation trial.

[SAD Placebo] A placebo liquid formulation matching the appearance and volume of BCD101 sachets, containing no active ingredient. Administered orally. Used for single dosing.

[MAD Placebo] A placebo liquid formulation matching the appearance and volume of BCD101 sachets, containing no active ingredient. Administered orally. Used for multiple dosing.

실험적: SAD-2(Placebo group)

2 Participants in the SAD-2(Placebo group) arm received a single oral dose of BCD101-P(2 sachets).

BCD101-P is a placebo liquid formulation identical in appearance and volume to BCD101-2, containing no active ingredient.

This study was conducted as a randomized, double-blinded, placebo-controlled, oral, single-dose, dose-escalation trial.

[SAD Placebo] A placebo liquid formulation matching the appearance and volume of BCD101 sachets, containing no active ingredient. Administered orally. Used for single dosing.

[MAD Placebo] A placebo liquid formulation matching the appearance and volume of BCD101 sachets, containing no active ingredient. Administered orally. Used for multiple dosing.

실험적: SAD-3(Placebo group)

2 Participants in the SAD-3(Placebo group) arm received a single oral dose of BCD101-P(3 sachets).

BCD101-P is a placebo liquid formulation identical in appearance and volume to BCD101-2, containing no active ingredient.

This study was conducted as a randomized, double-blinded, placebo-controlled, oral, single-dose, dose-escalation trial.

[SAD Placebo] A placebo liquid formulation matching the appearance and volume of BCD101 sachets, containing no active ingredient. Administered orally. Used for single dosing.

[MAD Placebo] A placebo liquid formulation matching the appearance and volume of BCD101 sachets, containing no active ingredient. Administered orally. Used for multiple dosing.

실험적: SAD-4(Placebo group)

2 Participants in the SAD-4(Placebo group) arm received a single oral dose of BCD101-P(4 sachets).

BCD101-P is a placebo liquid formulation identical in appearance and volume to BCD101-2, containing no active ingredient.

This study was conducted as a randomized, double-blinded, placebo-controlled, oral, single-dose, dose-escalation trial.

[SAD Placebo] A placebo liquid formulation matching the appearance and volume of BCD101 sachets, containing no active ingredient. Administered orally. Used for single dosing.

[MAD Placebo] A placebo liquid formulation matching the appearance and volume of BCD101 sachets, containing no active ingredient. Administered orally. Used for multiple dosing.

실험적: MAD-1(Placebo group)

2 Participants in the MAD-1(Placebo group) arm received BCD101-P(1 sachet), administered orally twice daily for 7 consecutive days.

BCD101-P is a placebo liquid formulation identical in appearance and volume to BCD101-1, containing no active ingredient.

This study was conducted as a randomized, double-blinded, placebo-controlled, multiple-dose, dose-escalation trial.

[SAD Placebo] A placebo liquid formulation matching the appearance and volume of BCD101 sachets, containing no active ingredient. Administered orally. Used for single dosing.

[MAD Placebo] A placebo liquid formulation matching the appearance and volume of BCD101 sachets, containing no active ingredient. Administered orally. Used for multiple dosing.

실험적: MAD-2(Placebo group)

2 Participants in the MAD-2(Placebo group) arm received BCD101-P(1 sachet), administered orally twice daily for 7 consecutive days.

BCD101-P is a placebo liquid formulation identical in appearance and volume to BCD101-2, containing no active ingredient.

The study was conducted as a randomized, double-blinded, placebo-controlled, multiple-dose, dose-escalation trial.

[SAD Placebo] A placebo liquid formulation matching the appearance and volume of BCD101 sachets, containing no active ingredient. Administered orally. Used for single dosing.

[MAD Placebo] A placebo liquid formulation matching the appearance and volume of BCD101 sachets, containing no active ingredient. Administered orally. Used for multiple dosing.

실험적: MAD-3(Placebo group)

2 Participants in the MAD-3(Placebo group) arm received BCD101-P(2 sachets), administered orally twice daily for 7 consecutive days.

BCD101-P is a placebo liquid formulation identical in appearance and volume to the active formulations, containing no active ingredient.

This study was conducted as a randomized, double-blinded, placebo-controlled, multiple-dose, dose-escalation trial.

[SAD Placebo] A placebo liquid formulation matching the appearance and volume of BCD101 sachets, containing no active ingredient. Administered orally. Used for single dosing.

[MAD Placebo] A placebo liquid formulation matching the appearance and volume of BCD101 sachets, containing no active ingredient. Administered orally. Used for multiple dosing.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Number of Participants With Adverse Events (Single-Ascending Dose, SAD)
기간: Day -1, Day 1, post-study visit (Day 4-7)

All adverse events occurring during the clinical trial following a single ascending dose of BCD101 will be collected and evaluated for seriousness, severity, and their relationship to the investigational product. Events will be coded using MedDRA System Organ Class and Preferred Term.

Day -1, Day 1, post-study visit (Day 4-7)
Physical Examination Abnormalities (SAD)
기간: Screening, Day -1, Day 1, post-study visit (Day 4-7)

A complete physical examination will be performed, and findings will be categorized as normal, not clinically significant (NCS), or clinically significant (CS). Only clinically significant (CS) findings will be classified as abnormalities for this outcome measure. Non-clinically significant deviations (NCS) will not be classified as abnormalities. The number of participants with clinically significant abnormalities will be reported.

Screening, Day -1, Day 1, post-study visit (Day 4-7)
Vital signs: Systolic and Diastolic Blood Pressure (SAD)
기간: Screening, Day -1, Day 1, post-study visit (Day 4-7)

Systolic and diastolic blood pressure will be measured after at least three minutes of rest in the seated position.

Screening, Day -1, Day 1, post-study visit (Day 4-7)
Vital signs: Heart Rate (SAD)
기간: Screening, Day -1, Day 1, post-study visit (Day 4-7)

Heart rate will be measured after at least three minutes of rest in the seated position.

Screening, Day -1, Day 1, post-study visit (Day 4-7)
Vital signs: Body Temperature (SAD)
기간: Screening, Day -1, Day 1, post-study visit (Day 4-7)

Body temperature will be measured after at least three minutes of rest in the seated position.

Screening, Day -1, Day 1, post-study visit (Day 4-7)
Electrocardiogram (ECG) Abnormalities (SAD)
기간: Screening, Day -1, Day 1, post-study visit (Day 4-7)

A standard 12-lead electrocardiogram will be performed, and ECG findings will be categorized as normal, not clinically significant (NCS), or clinically significant (CS). Only clinically significant (CS) findings will be classified as ECG abnormalities for this outcome measure. Non-clinically significant deviations (NCS) from reference ranges will not be classified as abnormalities. The number of participants with clinically significant abnormalities will be reported.

Screening, Day -1, Day 1, post-study visit (Day 4-7)
Laboratory Abnormalities (SAD)
기간: Screening, Day -1, Day 1, post-study visit (Day 4-7)

Clinical laboratory tests will include hematology, clinical chemistry, urinalysis, serology, and urine drug screening. Laboratory findings will be categorized as normal, not clinically significant (NCS), or clinically significant (CS). Only clinically significant (CS) findings will be classified as laboratory abnormalities for this outcome measure. Non-clinically significant deviations (NCS) from reference ranges will not be classified as abnormalities. The number of participants with clinically significant abnormalities will be reported.

Screening, Day -1, Day 1, post-study visit (Day 4-7)
Number of Participants With Adverse Events (MAD)
기간: Day -1 through Day 7, and post-study visit (Day 8-12)

All adverse events occurring during the clinical trial following a multiple ascending dose of BCD101 will be collected and evaluated for seriousness, severity, and their relationship to the investigational product. Events will be coded using MedDRA System Organ Class and Preferred Term.

Day -1 through Day 7, and post-study visit (Day 8-12)
Physical Examination Abnormalities (MAD)
기간: Screening, Day -1, Day 1, Day 7, post-study visit (Day 8-12)

A complete physical examination will be performed, and findings will be categorized as normal, not clinically significant (NCS), or clinically significant (CS). Only clinically significant (CS) findings will be classified as abnormalities for this outcome measure. Non-clinically significant deviations (NCS) will not be classified as abnormalities. The number of participants with clinically significant abnormalities will be reported.

Screening, Day -1, Day 1, Day 7, post-study visit (Day 8-12)
Vital signs: Systolic and Diastolic Blood Pressure (MAD)
기간: Screening, Day -1 through Day 7, and post-study visit (Day 8-12)

Systolic and diastolic blood pressure will be measured after at least three minutes of rest in the seated position.

Screening, Day -1 through Day 7, and post-study visit (Day 8-12)
Vital signs: Heart Rate (MAD)
기간: Screening, Day -1 through Day 7, and post-study visit (Day 8-12)

Heart rate will be measured after at least three minutes of rest in the seated position.

Screening, Day -1 through Day 7, and post-study visit (Day 8-12)
Vital signs: Body Temperature (MAD)
기간: Screening, Day -1 through Day 7, and post-study visit (Day 8-12)

Body temperature will be measured after at least three minutes of rest in the seated position.

Screening, Day -1 through Day 7, and post-study visit (Day 8-12)
Electrocardiogram (ECG) Abnormalities (MAD)
기간: Screening, Day -1, Day 1, Day 7, post-study visit (Day 8-12)

A standard 12-lead electrocardiogram will be performed, and ECG findings will be categorized as normal, not clinically significant (NCS), or clinically significant (CS). Only clinically significant (CS) findings will be classified as ECG abnormalities for this outcome measure. Non-clinically significant deviations (NCS) from reference ranges will not be classified as abnormalities. The number of participants with clinically significant abnormalities will be reported.

Screening, Day -1, Day 1, Day 7, post-study visit (Day 8-12)
Laboratory Abnormalities (MAD)
기간: Screening, Day -1, Day 1, Day 6-7, post-study visit (Day 8-12)

Clinical laboratory tests will include hematology, clinical chemistry, urinalysis, serology, and urine drug screening. Laboratory findings will be categorized as normal, not clinically significant (NCS), or clinically significant (CS). Only clinically significant (CS) findings will be classified as laboratory abnormalities for this outcome measure. Non-clinically significant deviations (NCS) from reference ranges will not be classified as abnormalities. The number of participants with clinically significant abnormalities will be reported.

Screening, Day -1, Day 1, Day 6-7, post-study visit (Day 8-12)

2차 결과 측정

결과 측정
측정값 설명
기간
Pharmacokinetic Parameters: Maximum Plasma Concentration (Cmax) (SAD)
기간: Day 1 (pre-dose through 12 hours post-dose)

Cmax will be determined from the plasma concentration-time profile following a single ascending dose of BCD101.

Day 1 (pre-dose through 12 hours post-dose)
Pharmacokinetic Parameter: Area Under the Concentration-Time Curve From Time Zero to the Last Measurable Concentration (AUC0-t) (SAD)
기간: Day 1 (pre-dose through 12 hours post-dose)

AUC0-t will be calculated using non-compartmental analysis following a single ascending dose of BCD101.

Day 1 (pre-dose through 12 hours post-dose)
Pharmacokinetic Parameter: Area Under the Concentration-Time Curve From Time Zero to Infinity (AUCinf) (SAD)
기간: Day 1 (pre-dose through 12 hours post-dose)

AUCinf will be calculated using non-compartmental analysis from the plasma concentration-time profile following a single ascending dose of BCD101.

Day 1 (pre-dose through 12 hours post-dose)
Pharmacokinetic Parameter: Time to Maximum Plasma Concentration (Tmax) (SAD)
기간: Day 1 (pre-dose through 12 hours post-dose)

Tmax will be determined from the plasma concentration-time profile following a single ascending dose of BCD101.

Day 1 (pre-dose through 12 hours post-dose)
Pharmacokinetic Parameter: Terminal Elimination Half-Life (t1/2) (SAD)
기간: Day 1 (pre-dose through 12 hours post-dose)

Terminal elimination half-life will be estimated from the terminal phase of the plasma concentration-time profile following a single ascending dose of BCD101.

Day 1 (pre-dose through 12 hours post-dose)
Pharmacokinetic Parameter: Maximum Plasma Concentration at Steady State (Cmax,ss) (MAD)
기간: Day 1 (pre-dose through 12 hours post-dose), Day 5 (pre-dose), Day 6 (pre-dose), Day 7 (pre-dose through 12 hours post-dose)

Cmax,ss will be determined from the plasma concentration-time profile at steady state following multiple ascending doses of BCD101.

Day 1 (pre-dose through 12 hours post-dose), Day 5 (pre-dose), Day 6 (pre-dose), Day 7 (pre-dose through 12 hours post-dose)
Pharmacokinetic Parameters: Area Under the Concentration-Time Curve Over the Dosing Interval (AUCtau,ss) (MAD)
기간: Day 1 (pre-dose through 12 hours post-dose), Day 5 (pre-dose), Day 6 (pre-dose), Day 7 (pre-dose through 12 hours post-dose)

AUCtau,ss will be calculated at steady state during multiple ascending dosing (Day 1-7).

Day 1 (pre-dose through 12 hours post-dose), Day 5 (pre-dose), Day 6 (pre-dose), Day 7 (pre-dose through 12 hours post-dose)
Pharmacokinetic Parameter: Area Under the Concentration-Time Curve From Time Zero to Infinity at Steady State (AUCinf,ss) (MAD)
기간: Day 1 (pre-dose through 12 hours post-dose), Day 5 (pre-dose), Day 6 (pre-dose), Day 7 (pre-dose through 12 hours post-dose)

AUCinf,ss will be calculated using non-compartmental analysis from the plasma concentration-time profile at steady state following multiple ascending doses of BCD101.

Day 1 (pre-dose through 12 hours post-dose), Day 5 (pre-dose), Day 6 (pre-dose), Day 7 (pre-dose through 12 hours post-dose)
Pharmacokinetic Parameter: Time to Maximum Plasma Concentration at Steady State (Tmax,ss) (MAD)
기간: Day 1 (pre-dose through 12 hours post-dose), Day 5 (pre-dose), Day 6 (pre-dose), Day 7 (pre-dose through 12 hours post-dose)

Tmax,ss will be determined from the plasma concentration-time profile at steady state following multiple ascending doses of BCD101.

Day 1 (pre-dose through 12 hours post-dose), Day 5 (pre-dose), Day 6 (pre-dose), Day 7 (pre-dose through 12 hours post-dose)
Pharmacokinetic Parameter: Terminal Elimination Half-Life at Steady State (t1/2,ss) (MAD)
기간: Day 1 (pre-dose through 12 hours post-dose), Day 5 (pre-dose), Day 6 (pre-dose), Day 7 (pre-dose through 12 hours post-dose)

Terminal elimination half-life at steady state will be estimated from the terminal phase of the plasma concentration-time profile following multiple ascending doses of BCD101.

Day 1 (pre-dose through 12 hours post-dose), Day 5 (pre-dose), Day 6 (pre-dose), Day 7 (pre-dose through 12 hours post-dose)
Pharmacokinetic Parameter: Accumulation Ratio (Rac) (MAD)
기간: Day 1 (pre-dose through 12 hours post-dose), Day 7 (pre-dose through 12 hours post-dose)

Rac will be calculated to assess the accumulation of BCD101 following multiple ascending doses.

Day 1 (pre-dose through 12 hours post-dose), Day 7 (pre-dose through 12 hours post-dose)

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2025년 9월 22일

기본 완료 (실제)

2026년 5월 15일

연구 완료 (실제)

2026년 5월 15일

연구 등록 날짜

최초 제출

2025년 11월 17일

QC 기준을 충족하는 최초 제출

2025년 12월 1일

처음 게시됨 (실제)

2025년 12월 15일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 29일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 28일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • BCD101

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다